Charles Sawyers, Larry Norton, and Kenneth Offit are being honored with special awards at the annual meeting of the world’s leading professional organization for cancer physicians and researchers.
Memorial Sloan-Kettering Clinical Genetics Service Chief Kenneth Offit discusses ways for women to clearly assess their risk for breast and ovarian cancer.
Genetic counselor Megan Harlan Fleischut discusses hereditary cancers and the services offered by Memorial Sloan-Kettering’s clinical genetics experts.
Memorial Sloan-Kettering investigators have found that some testicular cancers arising early in life may result from genetic changes that have not been inherited from either parent.
A team of Memorial Sloan-Kettering researchers reports that prostate cancer often takes an aggressive course in patients who have inherited mutations in the genes BRCA1 or BRCA2.
At Memorial Sloan-Kettering, as the genetics revolution continues to flourish, discoveries made in the laboratory are increasingly producing real-world benefits for cancer patients.
Memorial Sloan-Kettering’s Clinical Genetics Service has a staff of genetic counselors who offer information and education about genetic risk factors for families who have chosen to be tested.
Medical oncologist Andrew Seidman commented on a study that found that one in five black women with breast cancer were found to have inherited mutations on at least one of 18 genes linked to the disease.
Deputy Physician-in-Chief for Breast Cancer Programs Larry Norton spoke about hereditary breast cancer following Angelina Jolie’s announcement that she underwent a prophylactic mastectomy after learning she carries the BRCA gene mutation, which increases the risk for breast and ovarian cancer.
Breast cancer surgeon Monica Morrow spoke about preventive treatment options for women with a BRCA gene mutation, which increases the risk for breast and ovarian cancer.
Reconstructive surgeon Colleen McCarthy spoke about improvements in breast reconstruction following Angelina Jolie’s announcement that she underwent a prophylactic mastectomy after learning she carries the BRCA gene mutation, which increases the risk for breast and ovarian cancer.
Clinical Genetics Service Chief Kenneth Offit spoke about genetic testing and the increased risk of breast and ovarian cancer for women with BRCA gene mutations.
Breast cancer surgeon Deborah Capko explained the kind of prophylactic breast surgery Angelina Jolie received after learning she carries the BRCA gene mutation, which increases the risk for breast and ovarian cancer.
Breast cancer surgeon Alexandra Heerdt commended Angelina Jolie for sparking a conversation about hereditary breast cancer after learning she carries the BRCA gene mutation, which increases the risk for breast and ovarian cancer.
Surgical oncologist Sam Yoon spoke about a rare genetic mutation that increases the likelihood of developing gastric cancer and the prophylactic surgery some patients are opting to receive to reduce their chances of developing the disease.
An international study led by researchers at Memorial Sloan-Kettering Cancer Center has identified genetic variants in women with BRCA2 mutations that may increase or decrease their risk of developing breast cancer.
The recent marketing of “at home” genomic tests for disease risk may be premature, according to Dr. Kenneth Offit, MD, MPH, Chief of the Clinical Genetics Service at Memorial Sloan-Kettering Cancer Center (MSKCC).
An international group of investigators led by scientists at Memorial Sloan-Kettering Cancer Center and the National Cancer Institute has identified a new genetic marker of risk for breast cancer. Women with this DNA variation are at a 1.4 times greater risk of developing breast cancer compared to those without the variation.
The surgical removal of the ovaries has been widely adopted as a cancer-risk-reducing strategy for women with either BRCA1 or BRCA2 mutations. A new multicenter study led by researchers at Memorial Sloan-Kettering Cancer Center is the first prospective examination of the impact of this procedure in which BRCA2 mutation carriers were analyzed separately from BRCA1 mutation carriers.
Breast cancer risk varies widely among women who are carriers of the BRCA1 and BRCA2 mutations, according to a new study published in the January 9, 2008, issue of the Journal of the American Medical Association (JAMA).
ATLANTA, June 5, 2006 - A new multicenter study is the first to suggest that the prophylactic removal of the ovaries and fallopian tubes may provide a different benefit for women who carry a genetic mutation in the BRCA2 gene than for those who have a BRCA1 genetic mutation. The results of the study, which are being presented today at the annual American Society of Clinical Oncology meeting, also provide the strongest evidence to date that this surgery significantly reduces the overall risk of BRCA-associated breast and ovarian cancers.